Cargando…

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam

It is known that co‐administration of CYP3A inducers may decrease the effectiveness of oral contraceptives containing progestins as mono‐preparations or combined with ethinylestradiol. In a randomized clinical drug‐drug interaction study, we investigated the effects of CYP3A induction on the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiesinger, Herbert, Klein, Stefan, Rottmann, Antje, Nowotny, Bettina, Riecke, Kai, Gashaw, Isabella, Brudny‐Klöppel, Margarete, Fricke, Robert, Höchel, Joachim, Friedrich, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540325/ https://www.ncbi.nlm.nih.gov/pubmed/32275771 http://dx.doi.org/10.1002/cpt.1848

Ejemplares similares

Comparison of the Effects of Hysteroscopic Cold Broad Sword Play Combined with Estrogen and Progestin Sequential Therapy and Drospirenone and Ethinylestradiol Tablets in Patients with Severe Intrauterine Adhesion
por: Zhou, Liping, et al.
Publicado: (2022)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2021)

Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women
por: Momoeda, Mikio, et al.
Publicado: (2014)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

Ethinylestradiol/Chlormadinone Acetate: Dermatological Benefits
por: Guerra-Tapia, Aurora, et al.
Publicado: (2012)

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2018)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Inhibition of CYP3A-mediated Midazolam Metabolism by Kaempferia Parviflora
por: Kashiwabuchi, Yumika, et al.
Publicado: (2022)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Inhibitory effect of ethinylestradiol on coagulation factors in rats
por: Franco-Murillo, Yanira, et al.
Publicado: (2016)

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
por: Vázquez, Mercedes Gómez, et al.
Publicado: (2012)

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction
por: Yang, Jing, et al.
Publicado: (2011)

Progestin and Nuclear Progestin Receptor Are Essential for Upregulation of Metalloproteinase in Zebrafish Preovulatory Follicles
por: Liu, Dong Teng, et al.
Publicado: (2018)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Progestins and mammary cancer induction.
por: Coezy, E., et al.
Publicado: (1973)

The Progestin Revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control
por: Shoupe, Donna
Publicado: (2021)

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
por: Mathur, Ruchi, et al.
Publicado: (2008)

Manganese‐oxidizing bacteria mediate the degradation of 17α‐ethinylestradiol
por: Sabirova, Julia S., et al.
Publicado: (2008)

Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis
por: Muchova, Lucie, et al.
Publicado: (2015)

Detecting Traces of 17α-Ethinylestradiol in Complex Water Matrices
por: Zagalo, Paulo M, et al.
Publicado: (2020)

Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats
por: Nontakham, Jannarin, et al.
Publicado: (2022)

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
por: Denisov, Ilia G., et al.
Publicado: (2022)

Sex and Age Influence on Association of CYP450 Polymorphism with Midazolam Levels in Critically Ill Children
por: Flores-Pérez, Carmen, et al.
Publicado: (2022)

Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes
por: Abbott, Kodye L., et al.
Publicado: (2022)

Progestins and the endometrium in patients receiving tamoxifen
Publicado: (1999)

Ethinylestradiol/gestodene: Isolated cortical cerebral venous thrombosis: case report
Publicado: (2021)

Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
por: Liang, Angela L., et al.
Publicado: (2021)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
por: Brussee, Janneke M., et al.
Publicado: (2018)

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
por: Kanacher, Tobias, et al.
Publicado: (2020)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Efficacy of Low-Dose Estrogen–Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis
por: Iwata, Masaru, et al.
Publicado: (2022)

Removal of ecotoxicity of 17α-ethinylestradiol using TAML/peroxide water treatment
por: Mills, Matthew R., et al.
Publicado: (2015)

The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031
por: Tamura, Fumiya, et al.
Publicado: (2021)

Transcriptomic and Physiological Responses of Chlorella pyrenoidosa during Exposure to 17α-Ethinylestradiol
por: Zhang, Yurui, et al.
Publicado: (2022)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism
por: Rezaee, Mohammad Mahdi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q2u0nsi124v8bikbu4nniqoq5l